Eve™ CCHD Newborn Screening Application

 

Eve combines Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry with step-by-step instructions to assist clinicians in screening for Critical Congenital Heart Disease (CCHD)

Masimo - Eve CCHD Newborn Screening Application Eve application is available on the Rad-97® and Radical-7® Pulse Co-Oximeters®

Eve™ CCHD Newborn Screening Application

Eve combines Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry with step-by-step instructions to assist clinicians in screening for Critical Congenital Heart Disease (CCHD)

Eve simplifies the CCHD screening process, per an established protocol1, by providing visual instructions, animations, an automatic synchronisation algorithm, and a detailed, easy-to-interpret display of screening results

Masimo - Eve Animations provide visual

Animations provide visual guidance to assist clinicians through the screening process

Masimo - Eve automatic synchronisation algorithm

An automatic synchronisation algorithm, with an easy-to-interpret results screen, may reduce calculation errors

Masimo - Eve settings allow clinicians to incorporate perfusion index

Settings allow clinicians to incorporate perfusion index (Pi) measurement, which may increase sensitivity to detection of CCHD2

Masimo - Eve EMR integration

EMR integration via Masimo Patient SafetyNet™* or Iris Gateway® facilitates workflow and may help reduce reporting errors

Step-By-Step Instruction Improves Consistency and Workflow Efficiency

 
Masimo - Eve Step-By-Step Instruction Improves Consistency and Workflow Efficiency

CCHD Screening with Masimo SET® Pulse Oximetry

 

Improved Critical Congenital Heart Disease Screening Sensitivity vs. Clinical Assessment Alone3

Masimo - Improved Critical Congenital Heart Disease Screening
  • In a study of 39,821 infants, CCHD screening sensitivity increased from 63% with physical exam alone to 83% with physical exam and Masimo SET® pulse oximetry.2
  • In a study of 122,738 infants, CCHD screening sensitivity increased from 77% to 93% with the combined use of Masimo SET® and clinical assessment.3

Learn More About CCHD Screening with Masimo SET®

 

References:

  1. 1.

    Kemper AR, Mahle WT, Martin GR, Cooley WC, Kumar P, Morrow WR, Kelm K, Pearson GD, Glidewell J, Grosse SD, Howell, RR. Strategies for Implementing Screening for Critical Congenital Heart Disease. Pediatrics. 2011 Oct; 128(5):1259-67.

  2. 2.

    de-Wahl Granelli A et al. BMJ. 2009;338:a3037.

  3. 3.

    Zhao et al. Lancet. 2014 Aug 30;384(9945):747-54.

  4. * The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

RESOURCES

 

Masimo - Rad-97 with Eve Product Information
Eve

Product Information

Eve has obtained CE Marking. Not available in the U.S.

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, and precautions.

Learn More

Submit a request to receive more information and a Masimo representative will contact you shortly.

PLCO-003232/PLM-10862D-1019